Latest / Community Health Media
Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs
With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options?
Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient preferences can guide treatment selection.
Topics discussed:
Fixed-duration vs. continuous first-line therapy
Choosing among BTK inhibitor-based strategies
Acalabrutinib + venetoclax and venetoclax +…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.